Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.
Acquisition of Firefly Bio follows field-changing Revolution Medicines data
Mario Tama/Getty Images
By Jason MastJune 8, 2026
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field
Johnson & Johnson acerta aquisição da Firefly Bio por US$ 1 bilhão
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
Η Johnson & Johnson εξαγοράζει την Firefly Bio, εταιρεία ανάπτυξης τεχνολογίας φαρμάκων για τον καρκίνο, έναντι 1 δισεκ. δολαρίων
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
Incyte's Meury, now a buyer, sees $2B Vega deal as a step in blood treatments beyond Jakafi
The era of the one-size-fits-all Cancer drug is ending
Eli Lilly signs $1.9B gene-editing deal with Ascidian Therapeutics
Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a…
Adquirida está desenvolvendo uma plataforma proprietária de conjugados anticorpo-degradador voltada para cânceres impulsionados…
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug…
Η πλατφόρμα Firelink της Firefly χρησιμοποιεί αντισώματα για να απελευθερώσει ένα φάρμακο που αποικοδομεί πρωτεΐνες απευθείας στα…
Pharma group hopes acquisition will help to offset losses from expiring patents on blockbuster drugs
